# Pediatrics — Medical-Accuracy QA Log (web-grounded)

**Method:** same as prior logs — currency-sensitive guideline/pharmacotherapy claims + emergencies checked vs current AAP/ACIP guidelines/FDA approvals; prioritized spot-check, NOT per-sentence certification; attending sign-off required. sec: peds (BASE schema). 60 entries. **PRIOR-SESSION build.**

**Assessment up front:** very current, especially on the fast-moving prevention/guideline items — already had nirsevimab (RSV), the 2021 febrile-infant risk stratification, BRUE (replacing ALTE), IM epinephrine + early allergen introduction, and sickle-cell gene therapy. Two narrow specificity/currency additions applied (CF, jaundice).

---

## Batch 1 — 2026-07-18 (high-yield: prevention/guidelines + neonatology + emergencies)

### 2 ENHANCEMENTS APPLIED (specificity/currency)
- **peds-cystic-fibrosis** ✅ — said "CFTR modulator therapy (for eligible mutations) has transformed outcomes" generically. **Added:** named the highly effective triple combination **elexacaftor/tezacaftor/ivacaftor** (Trikafta), which now covers most patients.
- **peds-neonatal-jaundice** ✅ — used the Bhutani nomogram to "guide treatment" (the nomogram predicts risk; it isn't the treatment-threshold tool). **Added:** time phototherapy/exchange using the **current AAP (2022) hour-specific thresholds** (which incorporate gestational age + neurotoxicity risk factors); clarified Bhutani = risk prediction of subsequent hyperbilirubinemia.
- **Action:** APPLIED to transfer/res-resident-all.js; master regenerated + re-verified **1308/0-errors**.

### CONFIRMED current (verified vs AAP/ACIP/FDA; no change):
- **peds-bronchiolitis** — supportive care mainstay (no routine bronchodilators/steroids/antibiotics), prevention **nirsevimab (+ palivizumab high-risk)**, admit for hypoxia/dehydration/apnea. ✓ (nirsevimab present)
- **peds-febrile-infant** — neonates ampicillin+gentamicin (+acyclovir HSV) + admit, UTI most common SBI, proper urine, **validated risk-stratification for 29-60d** (reflects AAP 2021 guideline). ✓
- **peds-immunizations** — routine/catch-up, live-vaccine contraindications (immunocompromise/pregnancy; MMR/varicella >=12mo), true contraindication = anaphylaxis to component (mild illness/egg allergy NOT), HPV/Tdap/MenACWY at 11-12. ✓
- **peds-anaphylaxis-food-allergy** — **IM epinephrine (anterolateral thigh) first-line, immediately** (no absolute contraindication; antihistamines/steroids adjuncts), biphasic, autoinjector + action plan, **early allergen/peanut introduction (LEAP)**. ✓
- **peds-kawasaki** — **IVIG + aspirin within 10 days** (reduces coronary aneurysms), echo surveillance, CRASH criteria, one of few peds aspirin indications, incomplete KD in infants. ✓
- **peds-emergencies** — PALS (early respiratory support; arrest usually respiratory), isotonic fluid boluses (hypovolemic shock most common), **BRUE risk-stratification (most low-risk; replaced ALTE)**, safe sleep/SIDS, NAC/naloxone antidotes. ✓
- **peds-t1dm-dka** — **fluids first -> insulin infusion -> potassium**, **cerebral edema (leading cause of death; avoid rapid correction)**, new-onset presents in DKA, don't mistake for gastroenteritis. ✓
- **peds-sickle-cell** — VOC (hydration/analgesia/oxygen), acute chest syndrome emergency, **penicillin prophylaxis**, **hydroxyurea (raises HbF)**, TCD-guided stroke prevention, **curative transplant AND gene therapy** (already present), dactylitis/parvovirus B19. ✓
- **peds-uti** — proper (cath/clean-catch) urine, E. coli, **renal ultrasound after first febrile UTI, VCUG for recurrent/atypical (VUR)**, reduce scarring. ✓ (AAP UTI guideline)
- **peds-meningitis-sepsis** — empiric antibiotics immediately (ceftriaxone+vancomycin; ampicillin for Listeria neonates), don't delay for LP/CT, contact prophylaxis, neonatal (GBS/E.coli/Listeria) vs older (pneumococcus/meningococcus), CSF pattern. ✓
- **peds-asthma** — SABA (albuterol) relief, **ICS controller mainstay** (step up/down), exacerbations (SABA + systemic steroids + oxygen), silent chest ominous, foreign-body consideration. ✓ *(GINA/NAEPP ICS-formoterol/SMART is an option in older children/adolescents; entry is age-appropriate as written)*
- **peds-otitis-pharyngitis** — AOM (**high-dose amoxicillin or watchful waiting** older/mild), GABHS (penicillin/amoxicillin prevents ARF), **test before treating pharyngitis**, avoid amoxicillin in mono. ✓

## Running tally (peds)
- Checked: 14 high-yield claim-areas | CONFIRMED: 12 | ENHANCEMENTS applied: 2 (CF triple modulator naming; jaundice AAP 2022 thresholds) | CORRECTION: 0 | UNVERIFIED: 0
- **Very current.** Already had nirsevimab, 2021 febrile-infant stratification, BRUE, IM epinephrine + LEAP, sickle-cell gene therapy, cerebral-edema-caution DKA, AAP UTI imaging. The 2 additions were narrow specificity/currency.

## Next (peds)
- Remaining ~46 = neonatology (resuscitation, prematurity, neonatal sepsis/TORCH, RDS/TTN/MAS, hypoglycemia/IDM, newborn screening/IEM, NAS), development/well-child (milestones, FTT, well-child, autism/ADHD), other infections/exanthems (croup, CAP, viral exanthems), GI (gastroenteritis, pyloric stenosis, intussusception, constipation/Hirschsprung, ingestion, malrotation/volvulus), endo/genetics (congenital hypothyroidism, short stature/puberty, Down/genetic syndromes), heme/onc (anemias, ALL, solid tumors), renal (nephrotic, nephritis/HSP, hypertension), neuro (febrile seizures/epilepsy, CP, hypotonia), rheum/ortho (JIA, ortho conditions), adolescent (adolescent med, eating disorders, substance use), surgical (testicular torsion), and others (child abuse, enuresis/encopresis, immunodeficiency, septic arthritis/osteo, cleft, strabismus/amblyopia/ROP) - mostly stable diagnostic/management content, lower change-risk; lighter/attending pass.
